CAS 161748-29-4: GLP-1 (9-36) AMIDE (HUMAN, BOVINE, GUINEA PIG, MOUSE, PORCINE, RAT)

Custom research peptide; min purity 95%. For different specs please use the Peptide Quote Tool

Catalogue peptide; min. 95% purity

Natural cleavage product of GLP-1 which, unlike GLP-1, does not affect either insulin secretion or glucose homeostasis.  GLP-1(9-36) has low affinity for, and acts as an antagonist to, the GLP-1 receptor.GLP-1 (9-36) does however display unique biological activities such as beneficial cardiovascular effects and reducing the production of reactive oxygen species (ROS). GLP-1 (9-36) also exerts important physiological effects on neuronal plasticity in the hippocampus, and inhibits chemokine-induced migration of human CD4-positive lymphocytes.GLP-1 (9-36) is formed from the breakdown of biologically active but highly unstable GLP-1 (7-36) amide by the ubiquitous serine protease, dipeptidyl peptidase-IV (DPP-IV).

GLP-1 (9-36) amide trifluoroacetate is a bioactive peptide fragment derived from the full-length glucagon-like peptide-1 (GLP-1), an incretin hormone. It is typically obtained through enzymatic cleavage or synthetic processes involving solid-phase peptide synthesis. The mode of action of GLP-1 (9-36) amide involves binding to and modulating GLP-1 receptors, although it lacks the insulinotropic activity of its precursor GLP-1 (7-36) amide, making it a valuable tool for studying distinct signaling pathways and metabolic effects. The peptide is primarily utilized in scientific research to investigate its potential roles beyond glucose regulation, including cardiovascular effects, neuroprotection, and oxidative stress modulation. Its use underlines its importance in dissecting the physiological versus pharmacological roles of GLP-1 receptor signaling. GLP-1 (9-36) amide trifluoroacetate serves as an investigative tool in studies aiming to understand the complex interplay between different GLP-1 related peptides and their diverse physiological functions in metabolic disorders.

Glucagon-like peptide-1 (GLP-1) is efficiently degraded by the enzyme dipeptidyl peptidase IV (DPP IV), yielding the major metabolite GLP-1 (9-36) amide. GLP-1 (9-36) amide does not affect glucose disposal in mice either in the presence or absence of intact GLP-1 receptors or in the presence or absence of stimulated insulin levels. This suggests that the GLP-1 metabolite is not involved in the regulation of glucose homeostasis. Elahi et al. have shown that this GLP-1 metabolite acts as a weak insulinotropic agent and inhibits hepatic glucose production.

GLP-1 (9-36) amide is an antagonist at the human GLP-1 receptor.